328 Preclinical analyses and proof of concept clinical study of Epstein Barr Virus (EBV) specific genetically modified T cells against EBV associated malignancies

• Ling Li,
• Dan Wang,
• Xi Zhang,
• Yi Zhang,
• Mingzhi Zhang,
• Xin-Feng Chen,
• Xudong Zhang,
• Deping Han,
• Jianmin Huan,
• Renata Stripecke,
• Scott Burrows

Affiliations

Ling Li

NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, West China Hospital, Sichuan University, Chengdu, China

Dan Wang

Department of Pediatrics, Peking University Third Hospital, Beijing, China

Xi Zhang

Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Schoold of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

Yi Zhang

1 Shanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Mingzhi Zhang

3Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Xin-Feng Chen

2The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Xudong Zhang

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Deping Han

1Biosyngen Pte Ltd, Singapore, Singapore

Jianmin Huan

1Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Renata Stripecke

5Institute for Translational Immune-Oncology, Cancer Research Center Cologne-Essen (CCCE), University of Cologne, Cologne, Germany

Scott Burrows

7Queensland Institute of Medical Research, Herston, QLD, Australia